🔬 NEW IN SOLEIL RESEARCH™
Blinatumomab in High-Risk Pediatric B-ALL: What AIEOP-BFM ALL 2017 Found
Can part of an intensive chemotherapy regimen be replaced with targeted immunotherapy without sacrificing disease control—and possibly improve it?
A large international randomized phase 3 trial published in The New England Journal of Medicine provides strong evidence that, in one carefully defined setting, the answer may be yes. In children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (B-ALL), investigators replaced two conventional chemotherapy cycles after consolidation with two cycles of blinatumomab, a CD19-directed bispecific T-cell engager.
The result was clinically important: estimated 4-year event-free survival was higher with blinatumomab, while treatment-related infections and life-threatening adverse events were substantially less frequent. But this was not a chemotherapy-free regimen, follow-up remains relatively short for a pediatric cancer population, and neurotoxicity was more common with blinatumomab.
What the trial did
The AIEOP-BFM ALL 2017 Consortium randomized 709 of 768 eligible children with high-risk B-cell ALL in a 1:1 ratio after consolidation therapy. A total of 358 participants were assigned to receive two cycles of blinatumomab and 351 to receive two cycles of conventional chemotherapy.
The primary endpoint was event-free survival, measured from randomization to the first occurrence of protocol-treatment resistance, relapse, a second cancer, or death from any cause. The prespecified primary objective was to test whether estimated 4-year event-free survival would be 10 percentage points higher with blinatumomab.
The report presents a planned interim analysis with a median follow-up of 2.9 years. The primary analysis was intention-to-treat.
What the study found
Estimated 4-year event-free survival was 83.0% with blinatumomab versus 70.3% with chemotherapy, an absolute difference of 12.7 percentage points. The hazard ratio for a primary-endpoint event was 0.51 (95% CI, 0.35–0.73; P=0.0002).
That hazard ratio indicates that, over the observed follow-up period, the instantaneous rate of an event was approximately half as high in the blinatumomab group. It should not be interpreted as a literal 49% reduction in every individual child’s absolute risk.
The safety profile also differed substantially between groups. Trial-treatment-related infections occurred in 23.9% of the blinatumomab group versus 69.4% of the chemotherapy group. Life-threatening adverse events occurred in 0.5% versus 4.7%, respectively. One fatal life-threatening adverse event was reported in the blinatumomab group.
Not every safety signal favored blinatumomab. Neurotoxic events occurred in 12.0% with blinatumomab versus 3.2% with chemotherapy. Cytokine release syndrome of grade 2 or higher occurred in 1.1% of participants receiving blinatumomab.
Plain-language summary
Acute lymphoblastic leukemia is treated with combinations of medicines given in phases over time. Some chemotherapy blocks are highly effective but can also cause substantial toxicity, including serious infections.
In this trial, researchers did not remove chemotherapy from leukemia treatment. Instead, they replaced two specific chemotherapy cycles with blinatumomab, an immunotherapy that helps T cells recognize CD19-expressing B cells. Children assigned to blinatumomab had better estimated event-free survival and far fewer treatment-related infections than those assigned to the conventional chemotherapy cycles.
The finding supports a strategy of selective treatment substitution: using a different therapeutic mechanism to reduce exposure to particularly toxic chemotherapy blocks while preserving—or in this trial improving—disease control.
Methodological assessment
Overall assessment: high methodological quality for the randomized treatment question, with important uncertainty remaining about long-term durability and late effects.
Major strengths include the large randomized sample, international multicenter participation, an active conventional-chemotherapy comparator, intention-to-treat analysis, a clinically meaningful time-to-event primary endpoint, and a planned interim analysis. Randomization included 92.3% of eligible participants, reducing concern that the reported result reflects only a small selected fraction of the trial population.
The magnitude and consistency of the main findings also strengthen the interpretation. The event-free survival advantage was accompanied by a large reduction in treatment-related infections and fewer life-threatening adverse events, making the result clinically relevant beyond a statistical endpoint alone.
Important limitations and safety signals
The most important limitation is follow-up. The median follow-up was 2.9 years, yet the headline endpoint is an estimated 4-year event-free survival. Kaplan–Meier methods can estimate outcomes beyond the median follow-up when some participants have been observed longer, but the tail of the survival curve is necessarily supported by fewer patients. Longer follow-up is needed to establish whether the advantage persists and to characterize late relapse, late toxicity, second cancers, neurocognitive effects, and overall survival.
Generalizability is also specific. The participants were children with newly diagnosed high-risk B-cell ALL. The trial does not establish the same benefit in standard-risk pediatric ALL, T-cell ALL, adults with ALL, relapsed disease, or other leukemia subtypes.
The intervention replaced only two chemotherapy cycles after consolidation. It therefore should not be described as evidence that chemotherapy can be eliminated from frontline pediatric B-ALL treatment.
Finally, blinatumomab introduces its own toxicity profile. The higher frequency of neurotoxic events is clinically important, even though serious infection and life-threatening adverse events were lower overall. Cytokine release syndrome was uncommon at grade 2 or higher in this report, but it remains a treatment-specific risk requiring monitoring.
Funding and conflicts of interest
The paper reports support from Deutsche Krebshilfe, Associazione Italiana Ricerca contro il Cancro, Fondazione Maria Letizia Verga, Fondazione Tettamanti, Fondazione Città della Speranza, the Israel Cancer Association, the Chaim Association, and grants from the Ministry of Health of the Czech Republic.
The author list also includes two investigators with Amgen affiliations: Gerhard Zugmaier of Amgen Research in Munich and Faraz Zaman of Amgen in Thousand Oaks. The journal provides individual author disclosure forms with the article. These relationships do not by themselves invalidate the findings, but they are relevant context when interpreting a trial of blinatumomab and reinforce the importance of transparent disclosure, protocol prespecification, and long-term independent evaluation.
🔎 Soleil Insight
The advance is not that chemotherapy disappeared—it did not. The advance is strategic substitution.
This trial asks a more precise and clinically useful question than whether immunotherapy is simply “better” than chemotherapy. It tests whether two particularly toxic chemotherapy blocks can be replaced by a targeted T-cell engager within an established curative regimen. The answer, at this interim analysis, is encouraging: event-free survival improved while infectious toxicity fell sharply.
The next scientific question is durability. Pediatric leukemia treatment is judged not only by short-term disease control, but by sustained cure, late effects, neurodevelopment, quality of life, and the cumulative burden of therapy. Longer follow-up will determine whether the early advantage represents a durable improvement in the therapeutic index.
Bottom line
In this large randomized phase 3 trial, replacing two conventional chemotherapy cycles with blinatumomab improved estimated 4-year event-free survival in children with newly diagnosed high-risk B-cell ALL and substantially reduced treatment-related infections and life-threatening adverse events. Neurotoxicity was more frequent with blinatumomab, and median follow-up was 2.9 years.
The evidence is strong enough to support serious consideration of regimen redesign in this defined population, but it should not be generalized into claims of chemotherapy-free treatment or complete long-term certainty.
Original study: Schrappe M, Locatelli F, Valsecchi MG, et al.; AIEOP-BFM ALL 2017 Consortium. Blinatumomab for Replacing Chemotherapy in Pediatric Acute Lymphoblastic Leukemia. N Engl J Med. 2026;395:1075–1089. Published online September 16, 2026. DOI: 10.1056/NEJMoa2604166. ClinicalTrials.gov: NCT03643276.
Featured image credit: NIAID. Colorized scanning electron micrograph of a human B lymphocyte, used illustratively and not a trial participant or study specimen. Wikimedia Commons, licensed under CC BY 2.0.
This article is for scientific and educational communication and does not constitute individual medical advice.
Advancing Science. Empowering Humanity.